How CDMOs Can Digitalize Their Cell and Gene Therapy Processes
The demand for novel biologics is increasing on a global scale, making cell and gene therapies (CGT) among the most rapidly growing areas of the biopharma industry. In order to keep up with the rising demand, CGT developers are turning to CDMOs to outsource both development and manufacturing activities. CDMOs that use data analytics to address key industry challenges are at a competitive advantage when it comes to process optimization and delivery time for these therapies.
One of the most important considerations for companies working in the CGT (cell and gene therapy) field is how to ensure the commercial success of the product. By developing a strong relationship with the right CDMO, CGT developers can chart out a development, scale-up, and manufacturing plan that aligns with both their clinical and financial needs.